Objective: We investigated the determinants and clinical correlations of MRI-detected brain
volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase …

With 12 available US Food and Drug Administration approved medications for the treatment
of relapsing multiple sclerosis (MS), choosing an initial therapy is no longer a straightforward …

Objectives: Brain atrophy is associated with cognitive deficits in patients with clinically
isolated syndrome (CIS) and can predict conversion to clinical definite multiple sclerosis …

Multiple Sclerosis Journal 21 (6) 676 http://msj. sagepub. com change can be considered as
a reliable outcome marker. Another approach is to use T2 relaxometry to differentiate true …

Optic neuritis, myelitis and brainstem syndrome accompanied by a symptomatic MRI T2 or
FLAIR hyperintensity and T1 hypointensity are highly suggestive of multiple sclerosis (MS) in …

BACKGROUND AND PURPOSE: The relationship between lesion formation and brain
atrophy development in the early phase of multiple sclerosis is unclear. We investigated the …

Background Magnetic resonance imaging (MRI) is increasingly important for the early
detection of suboptimal responders to disease-modifying therapy for relapsing–remitting …

For patients presenting with clinically isolated syndrome, the treating clinician needs to
advise the patient on the probability of conversion to clinically definite multiple sclerosis. MR …

Background Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease
affecting the central nervous system (CNS) and is considered to be of autoimmune origin …

Background: There is little information available on global and on grey and white matter (GM
and WM) atrophy in primary progressive multiple sclerosis (PPMS) and on their relationship …